Cardiff Oncology, Inc.

NASDAQ•CRDF

CEO: Dr. Mark Erlander Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2004-07-27

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

連絡先情報

11055 Flintkote Avenue, San Diego, CA, 92121, United States

858-952-7570

www.cardiffoncology.com

時価総額

$133.37M

PER (TTM)

-2.9

19.7

配当利回り

52週高値

$4.56

52週安値

$1.48

52週レンジ

16%

順位60Top 89.2%

2.1

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$243.00K+0.00%

直近4四半期の推移

EPS

-$0.11+0.00%

直近4四半期の推移

フリーCF

-$5.97M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Onvansertib mCRC Trial Results CRDF-004 Phase 2 trial showed 72.2% ORR for 30mg Onvansertib arm versus SoC; well-tolerated profile observed.

R&D Spending Decreased Total research and development expenses decreased $1.5M to $35.3M in 2025, driven by lower clinical trial expenses.

Cash Position Maintained Cash, equivalents, and investments totaled $58.3M as of December 31, 2025; additional financing required for operations.

Strong IP Portfolio Owned and licensed IP includes 51 issued patents and 65 pending applications globally as of December 31, 2025.

リスク要因

Going Concern Uncertainty Recurring losses and negative operating cash flows raise substantial doubt about ability to continue without raising additional capital.

Nerviano License Breach Allegation Nerviano alleged material breach regarding patent ownership; termination could severely harm onvansertib rights and operations.

Clinical Development Risks Commercial viability hinges on successful advancement of onvansertib through trials and obtaining necessary regulatory approvals.

Limited Internal Capacity Reliance on third-party vendors for manufacturing and clinical trials creates risks of delays, cost overruns, or failure.

見通し

Planning Phase 3 Trial Plan to initiate CRDF-005 Phase 3 trial with registrational intent, contingent upon positive CRDF-004 results.

Biomarker Driven Development Laboratory efforts optimize patient selection using correlative biomarker analyses, including KRAS mutational burden assessment.

Interim CEO Appointed Mani Mohindru appointed Interim CEO effective January 27, 2026, following recent executive leadership changes.

Compete on Differentiation Future success depends on demonstrating superior safety, efficacy, and cost-effectiveness versus existing and emerging therapies.

同業比較

売上高 (TTM)

IPHA

$36.93M

-61.2%

CCCC

$35.95M

+1.0%

RANI

$1.20M

+0.0%

粗利益率 (最新四半期)

APLT

100.0%

+0.0pp

CCCC

83.6%

+13.4pp

CRDF

8.2%

+5842.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
PEPG	$464.74M	-2.4	-79.0%	9.8%
CYBN	$413.02M	-2.7	-61.5%	15.9%
FBRX	$397.85M	-10.9	-75.6%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

30.6%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月30日

EPS:-$0.15

売上高:$77.50K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし